Corporate Program - Symposia and Tutorials
All full conference delegates have access to these corporate events. Please note that when on site, you will be provided with an academic program and corporate guide. Please refer to the corporate guide for details on these symposia and tutorials, as well as details on the exhibit floor and company directory.
Wednesday May 18th
SYSTEMATIC EXCELLENCESM
Powerful platforms and flexible solutions that enable your work to flow.
2:30pm – 4:30pm
Willem Burger Zaal
|
2:30PM-2:35PM |
Noel Warner, PhD |
Welcome and introductions |
|
2:35PM-3:10PM |
Matthias Edinger, MD |
Isolation and Expansion of Human CD4+CD25+FOXP3+ Regulatory T Cells for Clinical Trials |
|
3:10 PM-3:45PM |
James Brooks, PhD |
A Serum-Free Human Bone Marrow Mesenchymal Stem Cell Expansion System with Growth Performance Exceeding Serum While Maintaining Multipotency and Immunophenotyping |
|
3:45PM-4:20PM |
Shelly Heimfeld, PhD |
Effect of PBSC and BM Graft Composition on GVHD, Relapse and Survival after Allogeneic Transplantation |
|
4:20PM-4:30PM |
Paul Falkenstein, PhD |
BD Commitment to Cell Therapy Enablement Closing Remarks |
New directions in cellular therapy
5:00pm – 7:00pm
Willem Burger Zaal
Agenda
Chair: Fred Falkenburg, Leiden University Medical Center, The Netherlands
|
5:00 p.m. |
Reducing alloreactivity by in vitro depletion of naive T cells |
|
5:25 p.m. |
The curative potential of γδT cells after allogeneic stem cell transplantation |
|
5:50 p.m. |
Coordinated isolation of CD8+ and CD4+ T cells recognizing CMV pp65, CMV IE-1, or HAdV hexon protein for highly specific adoptive immunotherapy |
|
6:15 p.m. |
Towards clinical-scale enrichment of mesenchymal stromal cells for orthopedic applications |
|
6:40 p.m. |
Discussion |
|
7:00 p.m. |
End |
Thursday May 19th
Biopreservation and Stability Considerations for Cellular Therapies – Clinical applications of HypoThermosol® and CryoStor® as ancillary or excipient reagents
12:30pm – 1:30pm
Fortis Bank Zaal
Speaker:
Aby J. Mathew, PhD
Senior Vice President and Chief Technology Officer
Cellular therapies and regenerative medicine utilize cell and tissue products sourced from blood, bone marrow, and various tissues. The clinical and commercial success of these products is potentially impacted by stability limitations, which include transport of the source material and biopreservation of the final cell or tissue product (either frozen or non-frozen). Join us for an updated discussion of the critical role and impact of biopreservation economics in the development and commercialization of regenerative medicine products. Topics include best practices in optimizing biopreservation workflow, including transportation and storage of source material and final dose, intermediate manufacturing process hold steps, and evaluation, selection, and validation of ancillary and excipient reagents. Comparative yield optimization and stability extension data will be presented. Case studies of clinical applications in a broad range of cellular therapies utilizing HypoThermosol® for non-frozen products and CryoStor® for cryopreserved products will be discussed.
Surface Matters for Cell Culture
12:30pm – 1:30pm
Jurriaanse Zaal
Speaker: Thomas Stelzer
This presentation will cover cell culture surface modifications on Thermo Scientific Nunc products, including energy treatment, ECM coating and surface graft.
Although in reality, it is difficult to accurately predict which surface chemistry would produce the best result for cell culture, Thermo Fisher Scientific works closely with the customer in designing and providing a variety of surfaces suitable for different types of cell culture.
Friday May 20th
Sepax 2 – the essential choice for automated processing in cellular therapy
12:30pm – 1:30pm
Willem Burger Zaal
The Biosafe Group is honoured to have 2 renowned experts presenting some of the leading advances in the field of cellular therapy.
Firstly, you will hear an overview of the use of the Sepax 2, our versatile new platform for cell processing, presented by the super-user Mr. Lutz Koerschgen from the Jose Carreras Cord Blood Bank in Düsseldorf, Germany. Mr. Koerschgen is a scientific partner who actively contributed during the development phase of this advanced technology.
Subsequently, Dr. MD Marcus Egermann from the clinic for orthopaedics and trauma surgery in Heidelberg, Germany, will share his extensive knowledge of using the Sepax 2 for bone marrow concentration in various orthopaedic applications.
 |
 |
GMP Cell Therapies: The New Reality
12:30pm – 1:30pm
Jurriaanse Zaal
CellGenix and Afc are honored to be hosting two of the leading innovators in the industry: Dr Don Healey and Dr. Jan Spanholtz.
Dr. Healey will discuss the challenges in autologous cell therapy from a manufacturing perspective. His talk will highlight the development of processes inherent in the scale up from institutional early phase clinical treatment of patients and the local collection and processing of cells as the process evolves into elements of compliance for moving to an external multi-center GMP environment. The challenges involve scale up process development, working with third party organizations, GMP reagents, closed system manufacturing, timely shipping of cellular products, controls, and more. The hurdles and bottlenecks described above will be reviewed in the context of Tovaxin, an autologous T-cell therapy for the treatment of Multiple Sclerosis.
Dr. Spanholtz will discuss the process of clinical grade generation of NK cells from Umbilical Cord Blood progenitor cells for immunotherapy using a closed system cell culture process. His talk will discuss the issues, development of protocols, and conditions required to facilitate clinical studies for the ex-vivo expansion of large numbers of cells in closed systems. He will also describe the dose of cells, washing procedure, and GMP reagents involved in the process without changing cell phenotype and cytotoxic activity for a successful phase 1 clinical study.
